Hypoxia is a common characteristic of all solid tumours (Ref. 1) and is a condition in which proliferating tumour cells are deprived of oxygen due to a limited blood supply from abnormal tumour microvasculature (Fig. 1 ). Hypoxic cells are at risk of stress-induced insults including oxidative DNA damage, DNA strand breaks and genetic aberrations, which can restrain growth and ultimately result in cell death. However, cancer cells show a range of genetic changes that improve survival and enable them to adapt to hypoxic conditions. As a result, hypoxic tumour cells continue to proliferate, are associated with a more invasive and metastatic phenotype and are usually resistant to conventional treatments such as radiotherapy and chemotherapy (Refs 2, 3, 4, 5, 6). Therefore, gaining a clearer understanding of the underlying molecular mechanisms involved in hypoxia signalling in cancer cells and how these processes might become deregulated in different cancer types is likely to result in better targeting of hypoxic tumour cells and more-effective treatments for solid tumours. A central component of hypoxia signalling in the cell is hypoxia-inducible factor (HIF), which is critically involved in both sensing and responding to changes in cellular oxygen (Ref. 7). This review outlines the therapeutic strategies used to target HIF/ hypoxic signalling in tumour cells and discusses recent advances made in this area.
The HIF pathway
HIF is a transcriptional complex activated in response to changes in cellular oxygen levels and mediates the expression of many genes (Refs 8, 9) . HIF target genes encode proteins that are involved in the regulation of various aspects of tumour biology, including oxygen transport, iron metabolism, glycolysis, glucose transport, cell survival and proliferation, angiogenesis, invasion and metastasis. HIF activity is deregulated in many human cancers, and this is most commonly due to the overexpression of HIF-a, the regulatory subunit of the HIF complex. Overexpression of HIF-a is usually associated with increased vascular density, severity of tumour grade, treatment failure and a poor prognostic outcome (Refs 10, 11). Blocking HIF activity or targeting HIF-1a expression in tumours has been shown to significantly slow tumour growth in xenograft Increased hypoxia is detected at increasing tumour size Figure 1 . Increased hypoxia is detected at increasing tumour size. The figure shows fluorescence imaging of human glioblastoma xenograft tumours. Tumours from the human glioblastoma multiforme tumour cell line E106 were transplanted subcutaneously into nude mice. Tumours were harvested when they reached a mean size of 2 mm (a), 4 mm (b), 6 mm (c), 8 mm (d) and 10 mm (e). Tumour sections were stained with antipimonidazole (green) to indicate areas of hypoxia, 9F1 (a monoclonal antibody to mouse endothelium; red) to assess vasculature, and Hoechst 33324 (blue) for nuclei. As tumour size increased, the vascular architecture became less organised. This figure was kindly provided by Dr Jan Bussink (Department of Radiation Oncology 874, Radboud University Nijmegen, The Netherlands) and is reprinted from Ref. 153 
HIF-1: structure and regulation
The HIFs belong to a family of structurally related basic-helix-loop-helix (bHLH)-containing proteins (Ref. 7) . The prototype of the family is HIF-1. HIF-1 consists of two subunits: the regulatory HIF-1a subunit and the ubiquitously expressed HIF-1b subunit (also known as aryl hydrocarbon receptor nuclear translocator, ARNT). HIF-1a protein is composed of four functional domains: a bHLH domain and a PER-ARNT-SIM (PAS) domain (involved in dimerisation and DNA binding), an oxygen-dependent degradation (ODD) domain (required for targeting to the proteasome and degradation), and two transactivation domains (N-TAD and C-TAD) required for transcriptional activation (Ref. 17) ( Fig. 2) . HIF-1b contains bHLH, PAS and transactivation domains (Ref. 18). Whereas HIF-1b is constitutively expressed in cells, the availability of HIF-1a is dependent on cellular oxygen levels. In normoxia (21% oxygen levels), HIF-1a protein is rapidly and continuously expressed and degraded (for review, see Ref. 9). The synthesis of HIF-1a protein is regulated by oxygen-independent mechanisms involving growth-factor-mediated activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways (Refs 19, 20) . HIF-1a protein degradation is controlled by the ODD domain, and deletion of the entire ODD region renders HIF-1a stable even in the absence of hypoxia signalling (Ref. 21). Hydroxylation of proline residues 402 and 564 within the ODD domain of HIF-1a mediates its interaction with the von Hippel-Lindau tumour suppressor protein (pVHL), which is the recognition component of an E3 ubiquitin ligase, leading to HIF-1a ubiquitination and subsequent degradation by the 26S proteasome (Refs 22, 23, 24, 25). The hydroxylation process is governed by three evolutionarily conserved HIF prolyl hydroxylases -PHD1 (EGLN2), PHD2 (EGLN1) and PHD3 (EGLN3) -and their activity depends on the availability of oxygen, iron, 2-oxoglutarate and ascorbate (Refs 26, 27). Interestingly, it has been shown by using small interfering RNA (siRNA) techniques that PHD2 plays a predominant role in controlling HIF-1a levels (Ref. 28). The basic-helix -loop -helix (bHLH) and PER -ARNT-SIM (PAS) domains of hypoxia-inducible factor 1a (HIF-1a) are involved in dimerisation and DNA binding; the oxygen-dependent degradation (ODD) domain is required for degradation via the proteasome; and the transactivation domains (N-TAD and C-TAD) are involved in transactivation activity. Hydroxylation of proline residues 402 and 564 within the ODD domain mediates its interaction with the von Hippel -Lindau tumour suppressor protein (pVHL). Hydroxylation of asparagine 803 in the C-TAD blocks its association with transcriptional coactivator p300/CBP. Under hypoxic conditions, prolyl hydroxylation within the ODD domain is inhibited and the interaction of HIF-1a with pVHL is prevented. As a result, HIF-1a ubiquitination and degradation is blocked and consequently the level of the protein increases. The accumulated HIF-1a translocates to the nucleus where it dimerises with HIF-1b (Ref. 7) via the bHLH and part of the PAS domain to form the HIF-1 complex.
Schematic representation of HIF-1α and its functional domains
HIF-1 recruits transcriptional coactivators such as p300/CBP (p300/CREBbinding protein) (Ref. 29) and binds to the hypoxia-response element (HRE) within the promoter region of HIF-1-responsive target genes (Ref. 30), thereby mediating their transcriptional activation.
The transcriptional activity of HIF-1 is also controlled by an asparagine hydroxylase known as FIH-1 (factor inhibiting HIF-1) (Refs 31, 32, 33, 34, 35) . In normoxia, hydroxylation of Asn803 in the C-TAD of HIF-1a blocks its association with p300/CBP. FIH-1 was also reported to interact with pVHL to modulate HIF-1a protein stabilisation (Ref. 35). Thus, FIH-1 acts as a negative regulator of HIF-1a to suppress transcriptional activity.
Other HIF-a family members
Two other HIF-a isoforms have been identified: HIF-2a and HIF-3a (Ref. 36). HIF-2a has a similar structure to HIF-1a (Ref. 37). Like HIF-1a, HIF-2a is rapidly induced in response to hypoxia, negatively regulated by the pVHL ubiquitin E3 ligase complex, and can mediate the transcriptional activation of a number of known HIF-1 target genes (Ref. 38). However, the expression of HIF-2a is cell-type specific and it has a distinct biological role from HIF-1a (Refs 39, 40, 41, 42, 43), with particular importance in renal cancer and vascular biology. In development, HIF-1a and HIF-2a were demonstrated to have nonoverlapping functions: HIF-1a 2/2 and HIF-2a 2/2 mouse embryos have different phenotypes and developmental defects (Ref. 40). HIF-2a is also expressed at a higher level than HIF-1a in several pVHL-defective renal carcinoma cell lines (Refs 42, 44), and various groups have reported that HIF-1 and HIF-2 can regulate both overlapping and distinct target genes (Refs 39, 41, 43 
HIF and cancer
In addition to hypoxia, loss-of-function mutations in several genes involved in the oxygen-sensing mechanism have also been shown to contribute to the overexpression of HIF-a (HIF-1a and HIF-2a) and activation of the HIF pathway in tumour cells ( Since HIF-a (HIF-1a and HIF-2a) is induced in cancer cells in response to hypoxia and growth factors, and as a result of known genetic abnormalties, it is no surprise then that HIF-a protein has been shown to be overexpressed in human tumour biopsy samples. Immunohistochemical analyses of paraffinembedded tissue sections have shown HIF-1a Figure 3 . HIF-1a expression is deregulated in cancer. Overexpression of hypoxia-inducible factor 1a (HIF-1a) and activation of the HIF pathway in cancer is caused by a combination of microenvironmental changes, such as changes in oxygen levels (hypoxia), pH and nutrients (deprivation), increases in growth factors, and genetic abnormalities leading to loss of tumour suppressor function, oncogenic activation or deregulated mitochondrial function. Increased HIF-a protein in cancer cells translocates to the nucleus, binds to HIF-1b, recruits coactivators (e.g. p300/CBP) and activates the transcription of multiple genes involved in angiogenesis (e.g. VEGF), metabolic adaptation (e.g. GLUT-1), cell survival (e.g. IGF-1) and metastasis (e.g. LOX, PAI-1) -thereby driving tumour progression. Abbreviations: FH, fumarate hydratase; GLUT-1, glucose transporter 1; HRG, heregulin; IGF-1, insulin-like growth factor 1; LOX, lysyl oxidase; p300/CBP, p300/ CREB-binding protein; p14ARF, alternate reading frame (ARF) product of CDKN2A (cyclin-dependent kinase inhibitor 2A) locus; PAI-1, plasminogen activator inhibitor 1; PTEN, phosphatase and tensin homologue; pVHL, von Hippel-Lindau tumour suppressor protein; SDH, succinate dehydrogenase; VEGF, vascular endothelial growth factor.
renal cell carcinoma (Ref. 62 ) and breast carcinoma (Refs 60, 61). This might be because the overexpression of HIF-1a, which often indicates significant levels of tumour hypoxia, is involved in mediating cellular adaptive responses that enable tumour cells to survive. Tumour hypoxia and HIF-1a overexpression is reported to correlate with an increased aggressiveness of tumour cell behaviour, angiogenesis (Ref. 57 ) and metastasis (Ref. 61) and can be used as a marker to predict outcome in patients with metastatic disease. Interestingly, a study in clear-cell renal cell carcinoma has shown that HIF-1a expression directly correlates with markers of apoptosis (p53) and growth inhibition (p21), the mTOR pathway (AKT, p27), the chemokine receptors CXCR3 and CXCR4, and proteins of the VEGF family (Ref. 62) . Therefore, induction of HIF-1a in many cancer types results in several consequences that could enable tumour cells to survive and continue to proliferate.
Surprisingly, not all tumours that exhibit HIF-1a overexpression have been found to be associated with decreased patient survival rates (Ref. 66 ). For example, in early-stage squamous cell carcinoma of the oral floor HIF-1a overexpression is associated with improved survival rates (Ref. 66) . This difference may arise from the fact that HIF-1a could function by having a dual role in early carcinogenesis. On the one hand, HIF-1a promotes tumour angiogenesis and cell survival when mediating an adaptive response, while on the other hand, in response to cellular stress HIF-1a cooperates with the apoptotic machinery (via induction of apoptotic genes or crosstalk to p53) to mediate tumour cell death (Ref. 67) . Indeed, the function of the HIFs in tumour progression might depend on the cell type and cellular context as well as the stage of carcinogenesis, and further work is needed to clarify this in order to establish when best to target the HIF pathway in cancer and whether certain cancer types would prove more or less sensitive to a HIF inhibitor.
Strategies to target the HIF pathway in cancer
In recent years, several strategies have been developed to identify direct and indirect inhibitors of HIF-a that function by blocking HIF-a (HIF-1a or HIF-2a) expression levels and/or HIF (HIF-1 or HIF-2) activity. These include cell-based reporter screens, antisense approaches, targeting key protein -protein interactions, increasing HIF-1a protein turnover or utilising a HIF oligonucleotide decoy (Table 1 ). In addition, therapeutic exploitation of other key pathways and mechanisms that are known to regulate HIF-1a protein availability (stability and synthesis) and HIF-1 activity could also potentially be utilised to target the HIF pathway in cancer ( Fig. 4 ). While the HIF transcriptional complex itself is a challenging therapeutic target, blockade of the HIF pathway and inhibition of HIF-a expression is therapeutically attractive because of its pivotal role in driving angiogenesis and tumour progression. Overexpression of HIF-1a in many cancers and deregulation of HIF activity offers a degree of selectivity for tumour cells over normal tissue (Ref. 68) , and blocking HIF-1a especially when in combination with conventional therapies has a significant impact on tumour growth (Ref. 69 ).
Targeting HIF-1a directly
As it functions as part of a transcriptional complex, targeting HIF-1a directly is challenging. Specific antisense approaches have been used to reduce HIF-1a expression and transcriptional activity (Ref. 70) , and a dominant negative form of HIF-1a has also been used (Ref. 71 ). Another approach is to inhibit HIF-1 transcriptional activity by blocking HIF-1a protein -protein interactions (Ref. 72) . For example, the binding between HIF-1a and the coactivator p300/CBP, and hence hypoxia-inducible transcription, has been attenuated by retroviral expression of a polypeptide (Ref. 73) , by the smallmolecule chetomin (Refs 13, 74) or by the use of the indazole compound YC-1 ( Refs 75, 76) . In addition, small molecules such as rolitetracycline (a semisynthetic pyrrolidnomethyltetracycline) that block HIF-1a -HIF-1b dimerisation by targeting the PAS domain offer a strategy to block HIF-1mediated activity in tumour cells by inhibiting the formation of the HIF-1 complex (Ref. 77 ).
Targeting HIF-1a expression and/or HIF-1 activity indirectly Prolyl hydroxylases
Mechanisms that regulate HIF-1a protein stability provide indirect means to target HIF-1a protein levels in tumour cells ( Fig. 4 ). For example, overexpression of PHDs (Ref. 78 ) enhances HIF-1a protein turnover and results in reduced HIF-1a protein availability in tumour cells. Thus, small-molecule activators of the PHDs -such as KRH1020053 -have been developed to reduce HIF-1a protein levels in tumour cells (Ref. 79 ). Alternatively, genetic blockade of SIAH2, which encodes an E3 ubiquitin ligase that ubiquinates PHD2 in hypoxia, leads to reduced HIF-1a availability (Ref. 80 ) and provides another potential mechanism for targeting HIF-1a protein stability (Ref. 81 ).
The p53 tumour suppressor protein
Understanding the relationship between HIF and other key signalling pathways can provide valuable therapeutic insight for developing strategies to target HIF indirectly ( Fig. 4) . For example, considerable progress has been made to our understanding of the molecular mechanisms by which HIF is regulated by the tumour suppressor protein p53, a transcription factor that plays a crucial role in monitoring cellular integrity. When the cell is stressed, p53 protein rapidly accumulates leading to either cell cycle arrest or apoptosis. However, p53 is mutated in over 50% of human cancers (Ref. 82 ). Mutated p53 is unable to transactivate downstream targets and is associated with malignant progression and metastasis ( Refs 83, 84) . While hypoxia induces cells to undergo p53-dependent apoptosis under some circumstances, cancer cells with dysregulated p53 function are able to survive ( Refs 85, 86, 87) .
p53 is involved in negatively regulating HIF-1a expression and HIF-1 activity ( Refs 88, 89, 90, 91) . While the molecular crosstalk between HIF-1 and p53 is complex, HIF-1a has been observed to bind to p53 in some cellular settings (Ref. 88 ). An in vitro study has provided biophysical evidence supporting the direct binding of p53 with It has been suggested that p53 can block HIF-1 transcriptional activity by competing with HIF-1a for p300 (Ref. 93) . p53, which itself is a transcription factor, requires the recruitment of p300 for its activity. Using an HRE -luciferase reporter assay to measure the transactivation of HIF-1, it has been demonstrated that low levels of exogenous p53 can block HIF-1 transcriptional activity and this effect can be relieved by overexpression of p300 in the cell (Ref. 93 ). This competitive binding of p53 for p300 was also confirmed in a separate in vitro transcription assay (Ref. 93) . While low levels of p53 can affect HIF-1 activity, high levels of p53 have been reported by several independent studies to block HIF-1a protein accumulation (Refs 54, 90, 93, 94) . Furthermore, loss of p53 has been observed to correlate with increased HIF-1a protein level and increased HIF-1 activity (Ref. 90) . Forced expression of HIF-1a in p53-expressing tumour cells upregulates VEGF expression (Refs 90, 95), neovascularisation and the growth of tumour xenografts (Ref. 90 ). Taken together, these studies clearly demonstrate that p53 negatively regulates HIF-1 transcriptional activity and HIF-1a protein levels and highlights the possibility that reactivating p53 may provide a means to target the HIF pathway in cancer (Fig. 4) .
Efforts have been made to identify agents that reactivate mutant p53 (Refs 96, 97) or activate wild-type p53 (Refs 98, 99) in cancer cells (Table 2) 
Other mechanisms for targeting HIF
Several high-throughput cell-based screening approaches using HRE -luciferase reporter systems have identified numerous HIF-1a small-molecule inhibitors that block tumour cell growth by blocking HIF-1a protein accumulation and HIF activity (Refs 100, 101), although their mechanism of actions remain to be understood. For example, topotecan -a topoisomerase inhibitor and known cytotoxic agent (Table 2) -was found to block HRE activity in a cell-based screen and was subsequently shown to suppress HIF-1a protein translation (Refs 102, 103 ). This inhibitor is currently being launched in the clinic to target ovarian and small-cell lung cancer cells. Interestingly, PX-478, another inhibitor of HIF-1a protein translation (although not identified through a cell-based HRE -luciferase reporter screen) is in Phase I clinical trials (Refs 104, 105, 106); however, the precise cellular target of PX-478 that is responsible for HIF-1a inhibition is not certain, and thus the development of clear clinical endpoints may prove challenging.
In addition to strategic efforts being developed to target the HIF pathway, many recognised anticancer drugs that target known regulators of HIF function have also been shown to block HIF-1a protein levels and/or HIF-1 activity ( Abbreviations: CDK, cyclin-dependent kinase; COX-2, cyclooxygenase 2; EGFR, epidermal growth factor receptor; HIF, hypoxia-inducible factor; HSP90, heat shock protein 90; MAPK, mitogen-activated protein kinase; 2-ME2, 2-methoxy estradiol; mTOR, mammalian target of rapamycin; PI3K, phosphoinositide 3-kinase; RITA, reactivation of p53 and induction of tumour cell apoptosis; VEGFR, vascular endothelial growth factor receptor.
(phosphorylated histone H2AX) accumulation, whereas tumours with only HIF-2a expression display increased c-Myc activity. The identified oncogenic pathways associated with these tumours may enable the strategic selection of combined targeted therapies to be used against these different tumour subtypes.
Translation of HIF inhibitors into the clinic
Hypoxic tumours are usually resistant to radiotherapy, as a result of the low level of oxygen molecules available to generate DNA strand breaks, and to chemotherapy, because of their slow divisional rate, abnormal vasculature and the upregulation of many genes that contribute to their aggressive phenotype. However, blocking HIF-1a renders tumour cells more susceptible to radiotherapy and conventional chemotherapeutic agents (Refs 13, 14) . The recent advances to our understanding of the HIF pathway have helped us to clarify its role in cancer and consequently enable the identification and design of novel therapies. Inhibitors that target the HIF pathway directly or indirectly are attractive and should prove useful in the treatment of most solid tumours including breast, prostate and renal carcinomas. Understanding the mechanism of action of different HIF pathway inhibitors is of particular importance when deciding when and how they would best be used in combination.
Which cancer types to target?
HIF-1a protein levels can be used as a prognosis marker in various cancers (Refs 131, 132, 133, 134) , as well as a predictive biomarker when designing new treatment regimes. Patients with VHLmutated sporadic clear-cell renal carcinomas exhibit high basal HIF-a expression and subsequently increased expression of VEGF and platelet-derived growth factor (PDGF). To date, the small-molecule tyrosine kinase inhibitors sunitinib and sorafenib that block VEGF and PDGF signalling have been the only agents shown to stabilise the disease, although increases in overall survival are disappointingly low (Refs 69, 135, 136, 137) . Both sunitinib and sorafenib have been approved for the treatment of renal cell carcinoma, where sunitinib is currently recommended as a first-line treatment and sorafenib as a second-line treatment option for people with advanced metastatic renal cell carcinoma (Refs 69, 138) . Clinical trials are under way to investigate the efficacy of these drugs in combination with conventional treatments or other small-molecule inhibitors and antibody therapies. Interestingly, a recent cell-based assay approach using renal carcinoma cells has identified STF-62247, an agent that functions to selectively induce cytotoxic and antitumour effects in pVHLdeficient renal carcinoma cells by inducing autophagy (Ref. 139) . The identification of STF-62247 illustrates the possibility of developing therapeutic agents that specifically target pVHL-deficient renal cancers (with high basal HIF-a expression), which account for around 75% of renal cell carcinomas (Ref. 139 ). Moreover, a pilot synthetic lethal screen has identified that inhibition of kinases such as CDK4/6 enhanced growth inhibition of pVHLdeficient renal cell carcinomas compared with matched pVHL-proficient renal cell carcinomas (Ref. 140 ), further highlighting those tractable targets for therapeutic intervention in renal cell carcinoma. It will be of particular interest to establish whether HIF inhibitors when used either alone or in combination with these other agents can provide a better therapeutic outcome for patients with advanced metastatic renal cell carcinoma.
Imaging hypoxia as a clinical tool
Effective imaging of hypoxia is important for cancer detection and diagnosis, assessment of therapy, as well as drug development. Imaging also provides a prognostic basis by which the effects of tumour hypoxia could be evaluated in personalised cancer treatment. For example, patients could be selected for hypoxia and high HIF-1a protein levels in their tumours, in order to enter them into clinical trials involving HIF inhibitors. Several direct and indirect methods for measuring hypoxia have been developed. Direct pO 2 measurement can be performed by an Eppendorf probe (a polarographic needle microelectrode) by direct insertion into tissues (Refs 141, 142) . Exogenous markers of hypoxia (such as pimonidazole and EF5) provide a more reliable measurement than using Eppendorf probes and can be used to detect the distribution of hypoxia in a small fraction of tumour ( Refs 143, 144, 145) . Positron emission tomography (PET) tracers such as [ 18 F]fluoromisonidazole have also been used to measure hypoxia throughout the body ( Refs 146, 147, 148) . PET imaging is sensitive and has a spatial and temporal resolution suitable for accessing the heterogeneity of local pO 2 . This technique was shown to have the ability to predict outcomes from radiation therapy by imaging hypoxic tissues ( Refs 149, 150, 151, 152) . Several magnetic resonance (MR)-based imaging (MRI) and spectroscopy strategies have been developed to assess tumour hypoxia directly or indirectly -namely 19 F-MRI and spectroscopy, high molecular weight dynamic contrast-enhanced MRI, electron paramagnetic resonance imaging and electron paramagnetic resonance oximetry. These methods can reliably and precisely reveal heterogeneity of oxygen distribution within tissues. As well as locating tumour and assessing treatment, MRI-based techniques can detect detailed metabolic and physiological information and PET imaging can reveal biochemical characteristics of the tumour, including metastases. With the preclinical development of many new HIF inhibitors being pursued currently, one challenge will be to define robust preclinical noninvasive imaging endpoints that are not only consistent with measurable effects on the HIF pathway in vivo, but that also directly relate to the mechanism of action and provide clear therapeutic insight with respect to the hypoxic tumour compartment.
Conclusions
Hypoxic tumours are usually resistant to killing by radiotherapy and conventional chemotherapies, rendering them highly aggressive and metastatic. Oxygen homeostasis in cells and the response to hypoxic stress is largely mediated by the HIF pathway. However, dysregulation of the HIF pathway occurs in many human cancers and usually correlates with a poor prognostic outcome using conventional treatments. Therefore, targeting the HIF pathway provides an attractive strategy to treat hypoxic and highly angiogenic tumours. The combination of HIF inhibitors with existing treatments or new targeted therapies may prove to be useful clinically.
However, the development of appropriate imaging strategies to accurately measure hypoxia in tumours along with the identification of suitable biomarker endpoints will accelerate the translation of new therapeutic combinations into the clinic as well as provide prognostic information that helps tailor specific treatments to different cancer types. HIF inhibitors are in preclinical and clinical development and these offer a novel and attractive approach for the treatment of solid tumours. Figure 1 . Increased hypoxia is detected at increasing tumour size. Figure 2 . Schematic representation of HIF-1a and its four functional domains. Figure 3 . HIF-1a expression is deregulated in cancer. Figure 4 . Strategies to target the HIF-1 pathway in cancer.
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